Dr. Clifford A. Hudis on the Importance of In-Breast Response Rates in Triple-Negative Breast Cancer
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer. Huddis says that while carboplatin does not definitively produce long-term outcomes, the drug does improve in-breast response rate, which could be important in some cases. He adds that those cases would include inoperable breast cancer that medical professionals would be looking to convert into an operable case.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
